A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

Acute Gout Clinical Trial

Official title:

A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00142558
• Other study ID #: 0663-081
• Secondary ID: MK0663-0812005_0
• Status: Completed
• Phase: Phase 4
• Start date: January 1, 2005
• Est. completion date: May 1, 2005

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: May 1, 2005
• Est. primary completion date: May 1, 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males or females at least 18 years of age who have acute gout.

Related Conditions & MeSH terms

• Acute Gout
• Arthritis, Gouty
• Gout

Intervention

Drug:
• MK0663; etoricoxib / Duration of Treatment: 5 Days

• Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient assessment of pain (0- to 4- Likert scale)
Secondary	Patient Global Assessment of Response to Therapy (0- to 4- point scale)
Secondary	Investigator Global Assessment of Response to Therapy (0- to 4- point scale)
Secondary	Tenderness of the study joint (0- to 3-point scale)
Secondary	Swelling of the study joint (0- to 3-point scale)